Modulation of the tumor microenvironment by the TLR9 agonist EnanDIM and combination with checkpoint inhibition for cancer immunotherapy

被引：0
|
作者：
Kapp, K. [1 ]
Volz, B. [1 ]
Oswald, D. [1 ]
Wittig, B. [2 ]
Schmidt, M. [1 ]
机构：
[1] Mologen AG, Translat Res, Berlin, Germany
[2] Free Univ Berlin, Fdn Inst Mol Biol & Bioinformat, Berlin, Germany
来源：
ANNALS OF ONCOLOGY | 2017年 / 28卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
56P
引用
收藏
页数：1
相关论文
共 50 条
  • [31] EnanDIM, a family of potent enantiomeric TLR9 agonists, modulate the tumor microenvironment and show single-agent antitumor effects in various syngeneic murine models
    Volz, Barbara
    Kapp, Kerstin
    Oswald, Detlef
    Wittig, Burghardt
    Schmidt, Manuel
    CANCER RESEARCH, 2018, 78 (13)
  • [32] TLR9 agonist lefitolimod to improve antitumor effect of checkpoint inhibitors in vivo.
    Schmidt, Manuel
    Kapp, Kerstin
    Volz, Barbara
    Oswald, Detlef
    Wittig, Burghardt
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [33] REGIONAL DELIVERY OF A TLR9 AGONIST TO BOOST CHECKPOINT INHIBITOR RESPONSIVENESS IN LIVER METASTASES
    Ghosh, Chandra
    O'Connell, Kyle
    Heatherton, Kara
    Laporte, Jason
    Guha, Prajna
    Cox, Bryan
    Katz, Steven
    Katz, Steven
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A637 - A637
  • [34] A new family of potent TLR9 agonists, EnanDIM, which inhibit tumor growth in various syngeneic murine models
    Volz, B.
    Kapp, K.
    Oswald, D.
    Wittig, B.
    Schmidt, M.
    EUROPEAN JOURNAL OF CANCER, 2018, 92 : S5 - S6
  • [35] Pressure-Enabled Drug Delivery (Pedd) of a Class C TLR9 Agonist in Combination With Checkpoint Inhibitor Therapy in a Pancreatic Cancer Murine Model
    Vicente, Diego
    Capacio, Benedict
    Narayanan, Jayanth Shankara
    Liu, Yujia
    LaPorte, Jason
    Cox, Bryan
    Jaroch, David
    Katz, Steven
    White, Rebekah
    ANNALS OF SURGICAL ONCOLOGY, 2023, 30 (SUPPL 1) : S110 - S110
  • [36] Pressure-Enabled Drug Delivery (PEDD) of a class C TLR9 agonist in combination with checkpoint inhibitor therapy in a murine pancreatic cancer model
    Capacio, Benedict A.
    Narayanan, Jayanth S. Shankara
    Vicente, Diego A.
    Liu, Yujia
    LaPorte, Jason P.
    Cox, Bryan F.
    Jaroch, David B.
    Katz, Steven C.
    White, Rebekah R.
    SURGERY, 2023, 174 (03) : 666 - 673
  • [37] Shaping the tumor microenvironment with Modified Vaccinia Virus Ankara and TLR9 ligand
    Preville, Xavier
    Rittner, Karola
    Fend, Laetitia
    ONCOIMMUNOLOGY, 2015, 4 (05):
  • [38] TLR9 plus STING Agonist Adjuvant Combination Induces Potent Neopeptide T Cell Immunity and Improves Immune Checkpoint Blockade Efficacy in a Tumor Model
    Eiro, Melisa D. Castro
    Hioki, Kou
    Li, Ling
    Wilmsen, Merel E. P.
    Kiernan, Caoimhe H.
    Brouwers-Haspels, Inge
    Meurs, Marjan van
    Zhao, Manzhi
    Wit, Harm de
    Grashof, Dwin G. B.
    Werken, Harmen J. G. van de
    Mueller, Yvonne M.
    Schliehe, Christopher
    Temizoz, Burcu
    Kobiyama, Kouji
    Ishii, Ken J.
    Katsikis, Peter D.
    JOURNAL OF IMMUNOLOGY, 2024, 212 (03): : 455 - 465
  • [39] Creating the tumor microenvironment for effective immunotherapy: Antitumor activity of intratumoral IMO-2125, a TLR9 agonist is further enhanced by inhibition of indoleamine-pyrrole 2,3-dioxygenase (IDO)
    Wang, Daqing
    Jiang, Wayne
    Lakshmi, Bhagat
    DiMuzio, Jillian
    Zhu, Fugang
    Agrawal, Sudhir
    CANCER RESEARCH, 2016, 76
  • [40] THE MTOR INHIBITOR EVEROLIMUS COOPERATES WITH THE TLR9 AGONIST IMO IN RENAL CELL CARCINOMA BY INTERFERING WITH BOTH TUMOR CELLS AND MICROENVIRONMENT
    Tortora, J. G.
    Rosa, R.
    Bianco, R.
    Gelardi, T.
    Garofalo, S.
    Marciano, R.
    Nappi, L.
    Formisano, L.
    Serpico, D.
    Damiano, V.
    ANNALS OF ONCOLOGY, 2010, 21 : 274 - 274
12345